BMO Capital Markets initiates coverage on Dyne Therapeutics with an Outperform rating, an $84 target, and a projected $4.3 billion peak sales for DYNE-101.
Latest Ratings for DYN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2020 | JP Morgan | Initiates Coverage On | Overweight | |
| Oct 2020 | Stifel | Initiates Coverage On | Buy | |
| Oct 2020 | Jefferies | Initiates Coverage On | Buy |
